Why is LLY.SW stock falling pre-market today?

LLY.SW stock fell **7.69%** pre-market on 24 Mar 2026 due to a rapid technical re-rate and valuation pressure. Low SIX volume suggests moves reflect cross-listed liquidity and broader sentiment rather than local news.

What are key valuation metrics for LLY.SW stock?

LLY.SW shows **EPS 18.18**, trailing PE **39.60**, price-to-sales **10.83**, and dividend yield **0.68%**. These metrics place the stock above Healthcare peers and increase sensitivity to growth misses.

What price targets and forecast exist for LLY.SW stock?

Meyka AI's model gives a conservative target **CHF 760.29**, base **CHF 974.73**, and bull **CHF 1,272.79**. The yearly forecast implies **35.37%** upside from **CHF 720.00**; forecasts are model projections, not guarantees.

How should traders manage risk with LLY.SW stock now?

Manage risk with smaller position sizes and clear stops. Watch **CHF 700.00** support and confirm moves on higher U.S. liquidity. Avoid adding into volatility without catalyst confirmation.

CH Stocks

Pre-Market LLY.SW Eli Lilly (SIX) -7.69% 24 Mar 2026: Watch CHF720 test CHF700

ByDanny Kontos March 24, 2026

LLY.SW stock opened pre-market down 7.69%, at CHF 720.00 on 24 Mar 2026 after a sharp re-rate on the SIX listing. We see short-term technical pressure and valuation concerns driving the move. Volume on the SIX snapshot is tiny at 2 shares, so price moves reflect cross-listing flows and sentiment more than local liquidity. We break down fundamentals, technicals, and Meyka AI forecasts to show possible support and targets for traders and investors.